Session » SLE – Clinical Poster III: Treatment

Date: Tuesday, November 12, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2524

24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States

9:00AM-11:00AM: Abstract Number: 2585

A Comparison of Risk of Ovarian Failure Following Intravenous Cyclophosphamide Therapy in Juvenile versus Adult Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2559

A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of Anifrolumab in Adults with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2579

A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity

9:00AM-11:00AM: Abstract Number: 2548

Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity

9:00AM-11:00AM: Abstract Number: 2564

Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2542

An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2526

Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2555

Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients

9:00AM-11:00AM: Abstract Number: 2545

Belatacept in Systemic Lupus Erythematosus (SLE) Kidney Transplant Patients

9:00AM-11:00AM: Abstract Number: 2519

Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE

9:00AM-11:00AM: Abstract Number: 2576

Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE

9:00AM-11:00AM: Abstract Number: 2581

Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2546

Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial

9:00AM-11:00AM: Abstract Number: 2523

Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2527

Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2561

Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells

9:00AM-11:00AM: Abstract Number: 2552

Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change

9:00AM-11:00AM: Abstract Number: 2516

Development of a Biomarker Panel for Prediction of Disease Flares in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2536

Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States

9:00AM-11:00AM: Abstract Number: 2554

Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?

9:00AM-11:00AM: Abstract Number: 2571

Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2528

Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2578

Effect of Omega-3 Fatty Acids on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2532

Effect of Treatment on Antiphospholipid Antibodies in SLE

9:00AM-11:00AM: Abstract Number: 2572

Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status

9:00AM-11:00AM: Abstract Number: 2575

Electronic Monitoring of Medication Adherence in Young Adults with Childhood-Onset Systemic Lupus Erythematosus over 12 Weeks

9:00AM-11:00AM: Abstract Number: 2560

Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease

9:00AM-11:00AM: Abstract Number: 2522

Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE

9:00AM-11:00AM: Abstract Number: 2562

Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018

9:00AM-11:00AM: Abstract Number: 2569

Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2556

Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN

9:00AM-11:00AM: Abstract Number: 2533

Hydroxychloroquine Increases Low C3 in SLE

9:00AM-11:00AM: Abstract Number: 2517

Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS

9:00AM-11:00AM: Abstract Number: 2573

Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels

9:00AM-11:00AM: Abstract Number: 2535

Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data

9:00AM-11:00AM: Abstract Number: 2568

Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study

9:00AM-11:00AM: Abstract Number: 2540

Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt

9:00AM-11:00AM: Abstract Number: 2550

Impact of Pathogenic and Protective Environmental Exposures on Autoimmune Disease—The Microbiome Effects on Lupus (MEL) Study

9:00AM-11:00AM: Abstract Number: 2538

Importance of Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) as a Novel Disease Activity Biomarker of Systemic Lupus Erythematous

9:00AM-11:00AM: Abstract Number: 2582

Incidence of Antimalarials-Induced Retinopathy in Inflammatory Rheumatic Diseases, Using OCT and Visual Field Test : A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 2537

Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)

9:00AM-11:00AM: Abstract Number: 2531

Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship

9:00AM-11:00AM: Abstract Number: 2584

Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review

9:00AM-11:00AM: Abstract Number: 2543

Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE

9:00AM-11:00AM: Abstract Number: 2539

Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 2565

Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2541

Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment

9:00AM-11:00AM: Abstract Number: 2580

Pharmacotherapies Targeting Type 2 SLE Symptoms

9:00AM-11:00AM: Abstract Number: 2563

PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease

9:00AM-11:00AM: Abstract Number: 2566

Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE

9:00AM-11:00AM: Abstract Number: 2549

Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials

9:00AM-11:00AM: Abstract Number: 2553

Prescription Opioid Use and Osteoporotic Fractures in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort

9:00AM-11:00AM: Abstract Number: 2583

Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies

9:00AM-11:00AM: Abstract Number: 2558

Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616

9:00AM-11:00AM: Abstract Number: 2567

Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates

9:00AM-11:00AM: Abstract Number: 2557

Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes – Case Control Study

9:00AM-11:00AM: Abstract Number: 2544

Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE

9:00AM-11:00AM: Abstract Number: 2521

Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)

9:00AM-11:00AM: Abstract Number: 2529

Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2547

Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use

9:00AM-11:00AM: Abstract Number: 2530

Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome

9:00AM-11:00AM: Abstract Number: 2574

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters

9:00AM-11:00AM: Abstract Number: 2577

SLE Disease Activity May Be Associated with Choroidal Thickness

9:00AM-11:00AM: Abstract Number: 2518

Time to Lupus Low Disease Activity State: Role of African-American Ethnicity

9:00AM-11:00AM: Abstract Number: 2520

Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial

9:00AM-11:00AM: Abstract Number: 2570

Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2551

Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Tests (CAT) in a Canadian Cohort of Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2534

Vitamin D Reduces Cardiovascular Risk Factors in SLE

9:00AM-11:00AM: Abstract Number: 2525

Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].